We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Treanda approved for chronic lymphocytic leukemia.
- Authors
Traynor, Kate
- Abstract
The article reports the approval of bendamustine hydrochloride for injection by the U.S. Food and Drug Administration (FDA) for the treatment of chronic lymphocytic leukemia. It relates that the drug developed by Cephalon Inc. will be marketed in the country as Treanda. It mentions that the FDA-approved labeling for bendamustine recommends that the drug be administered on the first and second days of a 28-day treatment cycle, with the treatment repeated for up to six cycles.
- Subjects
UNITED States; DRUG approval; CHRONIC lymphocytic leukemia treatment; UNITED States. Food &; Drug Administration; CEPHALON Inc.; PHARMACY
- Publication
American Journal of Health-System Pharmacy, 2008, Vol 65, Issue 9, p793
- ISSN
1079-2082
- Publication type
Article
- DOI
10.2146/news080034